Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 17, Number 8—August 2011

Research

Novel Arenavirus Infection in Humans, United States

Mary Louise Milazzo, Grant L. Campbell, and Charles F. FulhorstComments to Author 
Author affiliations: Author affiliations: University of Texas Medical Branch, Galveston, Texas, USA (M.L. Milazzo, C.F. Fulhorst); Centers for Disease Control and Prevention, Fort Collins, Colorado, USA (G.L. Campbell)

Main Article

Table 3

Antibody (immunoglobulin G) against WWAV and LCMV in paired serum samples from humans with acute central nervous system disease or undifferentiated febrile illnesses, United States*

Case-patient no.
 Age, y, at illness onset
 Days after illness onset
Antibody titer, WWAV
Antibody titer, LCMV Apparent
homologous virus
S1
 S2
 S1
 S2
 S1
 S2
1 32 14 44 <320 640 <320 <320 WWAV
2 65 15 61 <320 2,560 <320 <320 WWAV
3 38 14 33 <320 <320 5,120 5,120 LCMV
4 51 2 68 <320 <320 320 20,480 LCMV
5 59 24 38 <320 <320 320 5,120 LCMV
6 72 0 15 <320 <320 <320 640 LCMV
7 12 25 33 <320 <320 320 320 Indeterminate
8 25 47 123 <320 <320 320 320 Indeterminate

*WWAV, Whitewater Arroyo virus; LCMV, lymphocytic choriomeningitis virus; S1, first sample; S2, second (last) sample in paired samples.

Main Article

Page created: August 16, 2011
Page updated: August 16, 2011
Page reviewed: August 16, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external